Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Impact · against what's priced in

Johnson & Johnson's shares are under pressure as MedTech underperformance challenges the growth acceleration required by the current price, while one-time charges create near-term EPS volatility. The raised full-year outlook provides little catalyst as it merely confirms the growth trajectory the market already assumes.

JNJ−0.40

Challenges what's priced in

The price assumes